Vol.

No.

October 30, 2026Oct 30, 2026

DOWNLOAD THE PDF

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises New NOFO aims to shrink applications by 40%

Cover Story

NCI

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises

New NOFO aims to shrink applications by 40%

By Paul Goldberg

Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.

NCI

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

By Jacquelyn Cobb

Clinical

MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care

By Jacquelyn Cobb

Cancer History Project Free

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease

By Deborah Doroshow and Sara Willa Ernst

Lifesaving vaccines: Using KRAS to harness the power of the immune system

By Valerie Mehl

Podcast

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

Cancer Policy

HHS announces initiative to improve breast cancer screening and early detection

CDC Deputy Director Jennifer Shuford resigns

Cost of family insurance plans rose for workers in 2026, KFF survey finds

In Brief

Wells Messersmith named director of CU Anschutz Cancer Center

Ned Sharpless named president-elect of the AACR Academy

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

Rogerio Lilenbaum named enterprise physician lead at Advocate Health

Society of Surgical Oncology, IRCAD North America partner to advance hands-on surgical oncology education

University of Illinois’ Andrei Gartel receives NCI grant to study AML

Clinical Roundup

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Arcotatug tavatecan improves OS and PFS in patients with advanced gastric cancer, phase III study finds

Perioperative Imfinzi + Padcev improves EFS, OS, in MIBC, phase III trial finds

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

Mo-Rez achieves 62% ORR in platinum-resistant ovarian cancer, phase I study finds

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA releases guidance for sponsors developing gene therapies for rare diseases

FDA authorizes marketing of 24 nicotine pouches

EC expands Padcev + Keytruda approval to adults with resectable muscle-invasive bladder cancer regardless of cisplatin eligibility

CURRENT ISSUE

Recent Issues